Euphorbia kansui reactivates latent HIV

PLoS ONE

Volumn 11, Issue 12, 2016, Pages

  Cary, Daniele C ^a   Fujinaga, Koh ^a   Peterlin, B Matija ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 (4 CHLOROPHENYL) 2,3,9 TRIMETHYL 6H THIENO[3,2 F][1,2,4]TRIAZOLO[4,3 A][1,4]DIAZEPINE 6 ACETIC ACID TERT BUTYL ESTER; CD69 ANTIGEN; EUPHORBIA KANSUI EXTRACT; INGENOL; PLANT EXTRACT; UNCLASSIFIED DRUG; VORINOSTAT; DITERPENE;

ARTICLE; CD4+ T LYMPHOCYTE; CONCENTRATION RESPONSE; CONTROLLED STUDY; EFFECTIVE CONCENTRATION; EUPHORBIA; EUPHORBIA KANSUI; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; T LYMPHOCYTE ACTIVATION; VIRUS LATENCY; VIRUS REACTIVATION; VIRUS TRANSCRIPTION; ADULT; CELL CULTURE; CELL LINE; CHEMISTRY; CHINESE MEDICINE; DRUG EFFECTS; DRUG POTENTIATION; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; MALE; METABOLISM; MIDDLE AGED; PROCEDURES; REAL TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION;

ADULT; CD4-POSITIVE T-LYMPHOCYTES; CELL LINE; CELLS, CULTURED; DITERPENES; DRUG SYNERGISM; EUPHORBIA; FEMALE; FLOW CYTOMETRY; HIV INFECTIONS; HUMANS; MALE; MEDICINE, CHINESE TRADITIONAL; MIDDLE AGED; REAL-TIME POLYMERASE CHAIN REACTION; SIGNAL TRANSDUCTION; VIRUS LATENCY;

EID: 85006341644     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0168027     Document Type: Article

References (59)

1. UNAIDS (2015) AIDS by the numbers 2015. Joint United Nations Programme on HIV/AIDS (UNAIDS).
2. Marin B, Thiebaut R, Bucher HC, Rondeau V, Costagliola D, Dorrucci M, et al. (2009) Non-AIDS-defining deaths and immunodeficiency in the era of combination antiretroviral therapy. AIDS 23: 1743-1753. doi: 10.1097/QAD.0b013e32832e9b78 PMID: 19571723
3. Ho YC, Shan L, Hosmane NN, Wang J, Laskey SB, Rosenbloom DI, et al. (2013) Replication-competent noninduced proviruses in the latent reservoir increase barrier to HIV-1 cure. Cell 155: 540-551. doi: 10.1016/j.cell.2013.09.020 PMID: 24243014
4. Taube R, Peterlin M (2013) Lost in transcription: molecular mechanisms that control HIV latency. Viruses 5: 902-927. doi: 10.3390/v5030902 PMID: 23518577
5. Chun TW, Stuyver L, Mizell SB, Ehler LA, Mican JA, Baseler M, et al. (1997) Presence of an inducible HIV-1 latent reservoir during highly active antiretroviral therapy. Proc Natl Acad Sci U S A 94: 13193-13197. PMID: 9371822
6. Finzi D, Hermankova M, Pierson T, Carruth LM, Buck C, Chaisson RE, et al. (1997) Identification of a reservoir for HIV-1 in patients on highly active antiretroviral therapy. Science 278: 1295-1300. PMID: 9360927
7. Wong JK, Hezareh M, Gunthard HF, Havlir DV, Ignacio CC, Spina CA, et al. (1997) Recovery of replication-competent HIV despite prolonged suppression of plasma viremia. Science 278: 1291-1295. PMID: 9360926
8. Massanella M, Richman DD (2016) Measuring the latent reservoir in vivo. J Clin Invest 126: 464-472. doi: 10.1172/JCI80567 PMID: 26829625
9. Korin YD, Brooks DG, Brown S, Korotzer A, Zack JA (2002) Effects of prostratin on T-cell activation and human immunodeficiency virus latency. J Virol 76: 8118-8123. doi: 10.1128/JVI.76.16.8118-8123. 2002 PMID: 12134017
10. Bullen CK, Laird GM, Durand CM, Siliciano JD, Siliciano RF (2014) New ex vivo approaches distinguish effective and ineffective single agents for reversing HIV-1 latency in vivo. Nat Med 20: 425-429. doi: 10.1038/nm.3489 PMID: 24658076
11. Spivak AM, Bosque A, Balch AH, Smyth D, Martins L, Planelles V (2015) Ex Vivo Bioactivity and HIV-1 Latency Reversal by Ingenol Dibenzoate and Panobinostat in Resting CD4+ T Cells from Aviremic Patients. Antimicrob Agents Chemother.
12. Hori T, Barnor J, Huu TN, Morinaga O, Hamano A, Ndzinu J, et al. (2015) Procyanidin trimer C1 derived from Theobroma cacao reactivates latent human immunodeficiency virus type 1 provirus. Biochem Biophys Res Commun 459: 288-293. doi: 10.1016/j.bbrc.2015.02.102 PMID: 25727021
13. Cary DC, Fujinaga K, Peterlin BM (2016) Molecular mechanisms of HIV latency. J Clin Invest 126: 448-454. doi: 10.1172/JCI80565 PMID: 26731470
14. Pandelo Jose D, Bartholomeeusen K, da Cunha RD, Abreu CM, Glinski J, da Costa TB, et al. (2014) Reactivation of latent HIV-1 by new semi-synthetic ingenol esters. Virology 462-463: 328-339. doi: 10. 1016/j.virol.2014.05.033 PMID: 25014309
15. Sedore SC, Byers SA, Biglione S, Price JP, Maury WJ, Price DH (2007) Manipulation of P-TEFb control machinery by HIV: recruitment of P-TEFb from the large form by Tat and binding of HEXIM1 to TAR. Nucleic Acids Res 35: 4347-4358. doi: 10.1093/nar/gkm443 PMID: 17576689
16. He N, Pezda AC, Zhou Q (2006) Modulation of a P-TEFb functional equilibrium for the global control of cell growth and differentiation. Mol Cell Biol 26: 7068-7076. doi: 10.1128/MCB.00778-06 PMID: 16980611
17. Fujinaga K, Barboric M, Li Q, Luo Z, Price DH, Peterlin BM (2012) PKC phosphorylates HEXIM1 and regulates P-TEFb activity. Nucleic Acids Res 40: 9160-9170. doi: 10.1093/nar/gks682 PMID: 22821562
18. Kim YK, Mbonye U, Hokello J, Karn J (2011) T-cell receptor signaling enhances transcriptional elongation from latent HIV proviruses by activating P-TEFb through an ERK-dependent pathway. J Mol Biol 410: 896-916. doi: 10.1016/j.jmb.2011.03.054 PMID: 21763495
19. Liu P, Xiang Y, Fujinaga K, Bartholomeeusen K, Nilson KA, Price DH, et al. (2014) Release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein (snRNP) activates hexamethylene bisacetamide-inducible protein (HEXIM1) transcription. J Biol Chem 289: 9918-9925. doi: 10.1074/jbc.M113.539015 PMID: 24515107
20. Laird GM, Bullen CK, Rosenbloom DI, Martin AR, Hill AL, Durand CM, et al. (2015) Ex vivo analysis identifies effective HIV-1 latency-reversing drug combinations. J Clin Invest 125: 1901-1912. doi: 10. 1172/JCI80142 PMID: 25822022
21. Bartholomeeusen K, Fujinaga K, Xiang Y, Peterlin BM (2013) Histone deacetylase inhibitors (HDACis) that release the positive transcription elongation factor b (P-TEFb) from its inhibitory complex also activate HIV transcription. J Biol Chem 288: 14400-14407. doi: 10.1074/jbc.M113.464834 PMID: 23539624
22. Bartholomeeusen K, Xiang Y, Fujinaga K, Peterlin BM (2012) Bromodomain and extra-terminal (BET) bromodomain inhibition activate transcription via transient release of positive transcription elongation factor b (P-TEFb) from 7SK small nuclear ribonucleoprotein. J Biol Chem 287: 36609-36616. doi: 10. 1074/jbc.M112.410746 PMID: 22952229
23. Rasmussen TA, Schmeltz Sogaard O, Brinkmann C, Wightman F, Lewin SR, Melchjorsen J, et al. (2013) Comparison of HDAC inhibitors in clinical development: effect on HIV production in latently infected cells and T-cell activation. Hum Vaccin Immunother 9: 993-1001. doi: 10.4161/hv.23800 PMID: 23370291
24. Wei DG, Chiang V, Fyne E, Balakrishnan M, Barnes T, Graupe M, et al. (2014) Histone deacetylase inhibitor romidepsin induces HIV expression in CD4 T cells from patients on suppressive antiretroviral therapy at concentrations achieved by clinical dosing. PLoS Pathog 10: e1004071. doi: 10.1371/journal.ppat.1004071 PMID: 24722454
25. Contreras X, Schweneker M, Chen CS, McCune JM, Deeks SG, Martin J, et al. (2009) Suberoylanilide hydroxamic acid reactivates HIV from latently infected cells. J Biol Chem 284: 6782-6789. doi: 10. 1074/jbc.M807898200 PMID: 19136668
26. Routy JP, Tremblay CL, Angel JB, Trottier B, Rouleau D, Baril JG, et al. (2012) Valproic acid in association with highly active antiretroviral therapy for reducing systemic HIV-1 reservoirs: results from a multicentre randomized clinical study. HIV Med 13: 291-296. doi: 10.1111/j.1468-1293.2011.00975.x PMID: 22276680
27. Boehm D, Calvanese V, Dar RD, Xing S, Schroeder S, Martins L, et al. (2013) BET bromodomain-targeting compounds reactivate HIV from latency via a Tat-independent mechanism. Cell Cycle 12: 452-462. doi: 10.4161/cc.23309 PMID: 23255218
28. Spina CA, Anderson J, Archin NM, Bosque A, Chan J, Famiglietti M, et al. (2013) An in-depth comparison of latent HIV-1 reactivation in multiple cell model systems and resting CD4+ T cells from aviremic patients. PLoS Pathog 9: e1003834. doi: 10.1371/journal.ppat.1003834 PMID: 24385908
29. Blazkova J, Chun TW, Belay BW, Murray D, Justement JS, Funk EK, et al. (2012) Effect of histone deacetylase inhibitors on HIV production in latently infected, resting CD4(+) T cells from infected individuals receiving effective antiretroviral therapy. J Infect Dis 206: 765-769. doi: 10.1093/infdis/jis412 PMID: 22732922
30. Altfeld M, Kalife ET, Qi Y, Streeck H, Lichterfeld M, Johnston MN, et al. (2006) HLA Alleles Associated with Delayed Progression to AIDS Contribute Strongly to the Initial CD8(+) T Cell Response against HIV-1. PLoS Med 3: e403. doi: 10.1371/journal.pmed.0030403 PMID: 17076553
31. Darcis G, Kula A, Bouchat S, Fujinaga K, Corazza F, Ait-Ammar A, et al. (2015) An In-Depth Comparison of Latency-Reversing Agent Combinations in Various In Vitro and Ex Vivo HIV-1 Latency Models Identified Bryostatin-1+JQ1 and Ingenol-B+JQ1 to Potently Reactivate Viral Gene Expression. PLoS Pathog 11: e1005063. doi: 10.1371/journal.ppat.1005063 PMID: 26225566
32. Jiang G, Mendes EA, Kaiser P, Wong DP, Tang Y, Cai I, et al. (2015) Synergistic Reactivation of Latent HIV Expression by Ingenol-3-Angelate, PEP005, Targeted NF-kB Signaling in Combination with JQ1 Induced p-TEFb Activation. PLoS Pathog 11: e1005066. doi: 10.1371/journal.ppat.1005066 PMID: 26225771
33. Anderson L, Schmieder GJ, Werschler WP, Tschen EH, Ling MR, Stough DB, et al. (2009) Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol 60: 934-943. doi: 10.1016/j.jaad.2009.01.008 PMID: 19467365
34. Gama L, Abreu CM, Shirk EN, Price SL, Li M, Laird GM, et al. (2016) Reactivation of SIV reservoirs in the brain of virally suppressed macaques. AIDS.
35. Abreu CM, Price SL, Shirk EN, Cunha RD, Pianowski LF, Clements JE, et al. (2014) Dual role of novel ingenol derivatives from Euphorbia tirucalli in HIV replication: inhibition of de novo infection and activation of viral LTR. PLoS One 9: e97257. doi: 10.1371/journal.pone.0097257 PMID: 24827152
36. Jiang G, Mendes EA, Kaiser P, Sankaran-Walters S, Tang Y, Weber MG, et al. (2014) Reactivation of HIV latency by a newly modified Ingenol derivative via protein kinase Cdelta-NF-kappaB signaling. AIDS 28: 1555-1566. doi: 10.1097/QAD.0000000000000289 PMID: 24804860
37. Hou JJ, Wu WY, Liang J, Yang Z, Long HL, Cai LY, et al. (2014) A single, multi-faceted, enhanced strategy to quantify the chromatographically diverse constituents in the roots of Euphorbia kansui. J Pharm Biomed Anal 88: 321-330. doi: 10.1016/j.jpba.2013.08.049 PMID: 24113191
38. Shi QW, Su XH, Kiyota H (2008) Chemical and pharmacological research of the plants in genus Euphorbia. Chem Rev 108: 4295-4327. doi: 10.1021/cr078350s PMID: 18817355
39. Wang LY, Wang NL, Yao XS, Miyata S, Kitanaka S (2002) Diterpenes from the roots of Euphorbia kansui and their in vitro effects on the cell division of Xenopus. J Nat Prod 65: 1246-1251. PMID: 12350140
40. Gu XD, Zhang Q (2007) Clinical progress in the treatment of severe acute pancreatitis with integrative Chinese and Western medicine. Chin J Integr Med 13: 235-240. doi: 10.1007/s11655-007-0235-1 PMID: 17898960
41. Kupchan SM, Uchida I, Branfman AR, Dailey RG Jr., Fei BY (1976) Antileukemic principles isolated from euphorbiaceae plants. Science 191: 571-572. PMID: 1251193
42. Xing F, Tan Y, Yan GJ, Zhang JJ, Shi ZH, Tan SZ, et al. (2012) Effects of Chinese herbal cataplasm Xiaozhang Tie on cirrhotic ascites. J Ethnopharmacol 139: 343-349. doi: 10.1016/j.jep.2011.10.040 PMID: 22107835
43. Bensky D, Clavey S, Stoger E (2004) Chinese Herbal Medicine: Materia Medica ( ed Third). Vista, CA: Eastland Press.
44. Yu W, Ramakrishnan R, Wang Y, Chiang K, Sung TL, Rice AP (2008) Cyclin T1-dependent genes in activated CD4 T and macrophage cell lines appear enriched in HIV-1 co-factors. PLoS One 3: e3146. doi: 10.1371/journal.pone.0003146 PMID: 18773076
45. He J, Choe S, Walker R, Di Marzio P, Morgan DO, Landau NR (1995) Human immunodeficiency virus type 1 viral protein R (Vpr) arrests cells in the G2 phase of the cell cycle by inhibiting p34cdc2 activity. J Virol 69: 6705-6711. PMID: 7474080
46. Connor RI, Chen BK, Choe S, Landau NR (1995) Vpr is required for efficient replication of human immunodeficiency virus type-1 in mononuclear phagocytes. Virology 206: 935-944. doi: 10.1006/viro.1995. 1016 PMID: 7531918
47. Dutra RC, Claudino RF, Bento AF, Marcon R, Schmidt EC, Bouzon ZL, et al. (2011) Preventive and therapeutic euphol treatment attenuates experimental colitis in mice. PLoS One 6: e27122. doi: 10. 1371/journal.pone.0027122 PMID: 22073270
48. Passos GF, Medeiros R, Marcon R, Nascimento AF, Calixto JB, Pianowski LF (2013) The role of PKC/ ERK1/2 signaling in the anti-inflammatory effect of tetracyclic triterpene euphol on TPA-induced skin inflammation in mice. Eur J Pharmacol 698: 413-420. doi: 10.1016/j.ejphar.2012.10.019 PMID: 23099255
49. Cohn LB, Silva IT, Oliveira TY, Rosales RA, Parrish EH, Learn GH, et al. (2015) HIV-1 integration landscape during latent and active infection. Cell 160: 420-432. doi: 10.1016/j.cell.2015.01.020 PMID: 25635456
50. Archin NM, Margolis DM (2014) Emerging strategies to deplete the HIV reservoir. Curr Opin Infect Dis 27: 29-35. doi: 10.1097/QCO.0000000000000026 PMID: 24296585
51. Schaufelberger DE, Koleck MP, Beutler JA, Vatakis AM, Alvarado AB, Andrews P, et al. (1991) The large-scale isolation of bryostatin 1 from Bugula neritina following current good manufacturing practices. J Nat Prod 54: 1265-1270. PMID: 1800630
52. Beans EJ, Fournogerakis D, Gauntlett C, Heumann LV, Kramer R, Marsden MD, et al. (2013) Highly potent, synthetically accessible prostratin analogs induce latent HIV expression in vitro and ex vivo. Proc Natl Acad Sci U S A 110: 11698-11703. doi: 10.1073/pnas.1302634110 PMID: 23812750
53. DeChristopher BA, Loy BA, Marsden MD, Schrier AJ, Zack JA, Wender PA (2012) Designed, synthetically accessible bryostatin analogues potently induce activation of latent HIV reservoirs in vitro. Nat Chem 4: 705-710. doi: 10.1038/nchem.1395 PMID: 22914190
54. Fabricant DS, Farnsworth NR (2001) The value of plants used in traditional medicine for drug discovery. Environ Health Perspect 109 Suppl 1: 69-75.
55. Raskin I, Ribnicky DM, Komarnytsky S, Ilic N, Poulev A, Borisjuk N, et al. (2002) Plants and human health in the twenty-first century. Trends Biotechnol 20: 522-531. PMID: 12443874
56. Tu Y (2011) The discovery of artemisinin (qinghaosu) and gifts from Chinese medicine. Nat Med 17: 1217-1220. doi: 10.1038/nm.2471 PMID: 21989013
57. Wang C, Yang S, Lu H, You H, Ni M, Shan W, et al. (2015) A Natural Product from Polygonum cuspidatum Sieb. Et Zucc. Promotes Tat-Dependent HIV Latency Reversal through Triggering P-TEFb's Release from 7SK snRNP. PLoS One 10: e0142739. doi: 10.1371/journal.pone.0142739 PMID: 26569506
58. Livak KJ, Schmittgen TD (2001) Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods 25: 402-408. doi: 10.1006/meth.2001.1262 PMID: 11846609
59. Jablonski JA, Caputi M (2009) Role of cellular RNA processing factors in human immunodeficiency virus type 1 mRNA metabolism, replication, and infectivity. J Virol 83: 981-992. doi: 10.1128/JVI. 01801-08 PMID: 19004959